1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Co., Ltd.
  6. Summary
    4568   JP3475350009

DAIICHI SANKYO CO., LTD.

(4568)
  Report
Delayed Japan Exchange  -  05/23 02:00:00 am EDT
3397.00 JPY   +2.60%
05/19Jacobs Wins Deal to Support Clean-Up of Japan's Fukushima Nuclear Plant
MT
05/17LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
AQ
05/05AstraZeneca, Daiichi Sankyo Say US FDA Clears Enhertu to Treat Breast Cancer; AstraZeneca's Ultomiris Meets Primary Endpoint
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
05/17/2022 05/18/2022 05/19/2022 05/20/2022 05/23/2022 Date
3332(c) 3325(c) 3277(c) 3311(c) 3397 Last
4 578 600 3 677 600 4 463 500 6 187 000 5 020 300 Volume
-0.27% -0.21% -1.44% +1.04% +2.60% Change
More quotes
Estimated financial data (e)
Sales 2022 1 035 B 8 092 M 8 092 M
Net income 2022 70 466 M 551 M 551 M
Net cash position 2022 497 B 3 887 M 3 887 M
P/E ratio 2022 90,7x
Yield 2022 0,81%
Sales 2023 1 118 B 8 746 M 8 746 M
Net income 2023 85 324 M 667 M 667 M
Net cash position 2023 632 B 4 947 M 4 947 M
P/E ratio 2023 74,8x
Yield 2023 0,83%
Capitalization 6 346 B 49 636 M 49 636 M
EV / Sales 2022 5,65x
EV / Sales 2023 5,11x
Nbr of Employees 16 033
Free-Float 97,6%
More Financials
Company
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are... 
Sector
Pharmaceuticals
Calendar
06/07 | 06:30pmPresentation
More about the company
Ratings of Daiichi Sankyo Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about DAIICHI SANKYO CO., LTD.
05/19Jacobs Wins Deal to Support Clean-Up of Japan's Fukushima Nuclear Plant
MT
05/17LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recen..
AQ
05/05AstraZeneca, Daiichi Sankyo Say US FDA Clears Enhertu to Treat Breast Cancer; AstraZene..
MT
05/05Enhertu approved in the US for patients with HER2-positive metastatic breast cancer tr..
AQ
05/05AstraZeneca, Daiichi's Breast Cancer Treatment Wins US Approval
MT
05/05AstraZeneca's Enhertu Approved in US for Metastatic Breast Cancer Treatment
DJ
04/28ENHERTU (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in t..
AQ
04/28AstraZeneca - Based on DESTINY-Breast04 results where AstraZeneca and Daiichi Sankyo's ..
AQ
04/28Daiichi Sankyo's FY22 Attributable Profit Falls 12% on Higher Expenses
MT
04/27SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Wednesday
MT
04/27AstraZeneca, Daiichi Sankyo Get FDA Breakthrough Therapy Designation for Breast Cancer ..
MT
04/27Enhertu granted BTD for HER2-low breast cancer
AQ
04/27TRANSCRIPT : Daiichi Sankyo Company, Limited, Q4 2022 Earnings Call, Apr 27, 2022
CI
04/27AstraZeneca's Enhertu Gets US FDA's Breakthrough Therapy Designation In Breast Cancer T..
MT
04/27AstraZeneca's Enhertu Drug Granted Breakthrough Therapy Designation in US
DJ
More news
News in other languages on DAIICHI SANKYO CO., LTD.
05/19Jacobs remporte un contrat pour soutenir le nettoyage de la centrale nucléaire japonais..
05/05AstraZeneca, Daiichi Sankyo déclarent que la FDA américaine autorise Enhertu pour le tr..
05/05Le traitement du cancer du sein d'AstraZeneca et de Daiichi obtient l'approbation des É..
04/28Le bénéfice attribuable de Daiichi Sankyo pour l'exercice 22 chute de 12 % en raison de..
04/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé progressent avant la cloche d..
More news
Analyst Recommendations on DAIICHI SANKYO CO., LTD.
More recommendations
Chart DAIICHI SANKYO CO., LTD.
Duration : Period :
Daiichi Sankyo Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 3 311,00 JPY
Average target price 3 942,86 JPY
Spread / Average Target 19,1%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Executive Officer & Head-Corporate Planning
Wataru Takasaki Head-Research & Development
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO CO., LTD.13.20%49 636
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707